Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 Study.
Authors
Yao, JFazio, N
Singh, S
Buzzoni, R
Carnaghi, C
Wolin, E
Tomasek, J
Raderer, M
Lahner, H
Voi, M
Pacaud, L
Lincy, J
Valle, Juan W
Delle Fave, G
Van Cutsem, E
Oh, D
Strosberg, J
Kulke, M
Pavel, M
Affiliation
University of Texas/MD Anderson Cancer Center, HoustonIssue Date
2017